Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

(2017) Magali Lemaitre et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Crohn's disease

(2017) Joana Torres et al.   LANCET

Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab

(2016) Mark T Osterman et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis

(2016) Chelle L. Wheat et al.   Gastroenterology Research and Practice

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

(2015) A. Bourrier et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis

(2015) David S. Kotlyar et al.   Clinical Gastroenterology and Hepatology

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study

(2014) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry

(2014) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease

(2013) Björn Pasternak et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

(2013) Mark T. Osterman et al.   GASTROENTEROLOGY

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

(2011) Craig Leonardi et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease

(2011) Laurent Peyrin–Biroulet et al.   GASTROENTEROLOGY

The Natural History of Adult Crohn's Disease in Population-Based Cohorts

(2009) Laurent Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

(2009) G R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab safety in global clinical trials of patients with Crohnʼs disease

(2009) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

(2009) Laurent Beaugerie et al.   LANCET